FDA approves Pfizer drug for rare blood cancer

by The Associated Press

Pfizer Inc. says the Food and Drug Administration on Tuesday approved its new drug to treat a rare form of blood and bone marrow cancer.

Pfizer's Bosulif is a daily pill to treat patients with a specific genetic variation. The disease is one of four types of the blood cancer, and accounts for about 15 percent of leukemia cases.

The disease, which usually affects seniors, causes the bone marrow to produce unhealthy that do not grow and die like normal cells. Instead, the cells buildup in the bone marrow and crowd out healthy cells that are needed to fight off infections.

An estimated 5,430 people will be diagnosed with this year, according to the FDA.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Marqibo approved for rare leukemia

Aug 10, 2012

(HealthDay) -- Marqibo (vincristine sulfate liposome injection) has been approved by the U.S. Food and Drug Administration to treat adults with a rare form of blood and bone marrow cancer, Philadelphia chromosome negative ...

Drug makes leukemia more vulnerable to chemo

Mar 20, 2012

(Medical Xpress) -- Doctors at Washington University School of Medicine in St. Louis have shown that a new drug makes chemotherapy more effective in treating acute myeloid leukemia, a cancer of the white blood cells. Instead ...

Recommended for you

FDA OKs Cubist antibiotic for serious infections

12 hours ago

The Food and Drug Administration has approved a new medicine to fight complex infections in the abdomen and urinary tract, the fourth antibiotic the agency has approved since May.

Xtoro approved for swimmer's ear

Dec 18, 2014

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

Drug interaction identified for ondansetron, tramadol

Dec 18, 2014

(HealthDay)—In the early postoperative period, ondansetron is associated with increased requirements for tramadol consumption, according to a review and meta-analysis published online Dec. 10 in Anaesthesia.

New system targets germs in donated blood plasma

Dec 17, 2014

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.